Fenofibrate Nanocrystalize
SPE2D220R0073 · DEPT OF DEFENSE
A PHARMACEUTICAL PREPARATION MANUFACTURING solicitation, with responses due 2020-10-23. AwardCast estimates what this specific solicitation will close for, before you bid.
What's being bought
Modification P00004 SPE2D2-21-D-0131 No Cost-Settlement Termination for Convenience. Modification P00003 SPE2D2-21-D-0131 to incorporate FAR Claluse 52.204-27 Prohibition on a Bytedance Covered Application (JUN 2023) into contract. Option Year 2 P00002 SPE2D2-21-D-0131 to invoke option period of Apr
Comparable recent awards in PHARMACEUTICAL PREPARATION MANUFACTURING
| Winner | Award value | Offers | Date |
|---|---|---|---|
| PRIORITY HEALTHCARE DISTRIBUTION INC | $16K | 1 | 2026-07-02 |
| REGIMED MEDICAL | $293K | 7 | 2026-07-02 |
| COVERMYMEDS PHARMACY LLC | $16K | 1 | 2026-07-02 |
| SRI INTERNATIONAL | $49.9M | 7 | 2026-07-02 |
| UNITED THERAPEUTICS CORP | $17K | 1 | 2026-07-02 |
Questions
What is solicitation SPE2D220R0073?
Fenofibrate Nanocrystalize, issued by DEPT OF DEFENSE, under NAICS 325412 (PHARMACEUTICAL PREPARATION MANUFACTURING). Responses are due 2020-10-23.
What do similar contracts close for?
Comparable closed awards in this category ran from $16K to $49.9M, across 5 awards shown above. Those are historical results, not a forecast for this solicitation.
Explore the market
Forecast Report — what a specific solicitation will close for: the predicted price range, the competition to expect, and comparable awards already closed. Before you price your bid.
Every forecast is scored against the real award once it becomes public. See the track record.
Closed awards from public federal data, not the forecast. One email, no account.
Or get the forecast for this solicitation — $49, one report.